Lilly Said to Near Deal for Psychedelic Drugmaker AtaiBeckley
Eli Lilly nears deal to buy psychedelic drugmaker AtaiBeckley
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
Eli Lilly is reportedly near a deal to acquire AtaiBeckley, a psychedelic drugmaker. According to reports, the acquisition would be worth $2.8 billion. Coverage from Yahoo Finance, CNBC, and Bloomberg News emphasizes the potential takeover and its impact on AtaiBeckley's stock. The stock has seen a significant increase, with some reports indicating a rise of 66%. What to watch next is the official announcement of the acquisition and how it will affect the pharmaceutical industry, with multiple outlets including Reuters and Barron's covering the developments
Synthesized by headlinez.news from the headlines below under a strict no-invention contract. Updated just now.
Quick answers
What is the reported value of the acquisition?
$2.8 billion
How has AtaiBeckley's stock been affected?
It has seen a significant increase, with some reports indicating a rise of 66%
Which companies are involved in the acquisition?
Eli Lilly and AtaiBeckley
Coverage (9)
- Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions PR Newswire · 4h ago
- ATAI Stock Eyes Rocketing Back To 4-Year Highs: VC Sees Up to 105% Takeover Premium From Eli Lilly Yahoo Finance · 4h ago
- Eli Lilly to buy psychedelics maker AtaiBeckley for $2.8 billion as experimental treatments gain traction CNBC · 4h ago
- Psychedelic drugmaker AtaiBeckley shares soar 66% on Eli Lilly buyout talks (LLY:NYSE) Seeking Alpha · 4h ago
- This Psychedelic Pharma Stock Is Soaring 50% on Report of Eli Lilly Takeover Talks Barron's · 4h ago
- Here Is Why AtaiBeckley (ATAI) Is One Of The 10 Best Stocks Under $10 That Could Triple Yahoo Finance · 4h ago
- Eli Lilly nears deal to buy psychedelic drugmaker AtaiBeckley, Bloomberg News reports Reuters · 4h ago
- Lilly Said to Near Deal for Psychedelic Drugmaker AtaiBeckley Bloomberg.com · 4h ago
- Lilly to Buy Psychedelic Firm AtaiBeckley for Up to $3.8 Billion Bloomberg.com · 13h ago
Topics
Related trends
New Alzheimer’s drug could stop disease
A potential breakthrough in Alzheimer’s treatment sparks debate over drug efficacy and healthcare costs as clinical trials advance.
Johnson & Johnson CFO Says Guidance Hike Is Just the Start
Johnson & Johnson shares dipped despite an earnings beat and raised guidance as investors weigh strong medicine sales against medical technology underperformance.
An experimental Alzheimer's drug shows some promise as researchers hunt new approaches
Biogen’s experimental tau-targeting drug, diranersen, has triggered market volatility following the release of mixed clinical trial data.
All eyes on data on Biogen’s tau therapy
Biogen’s tau-targeting Alzheimer’s drug shows early promise in slowing cognitive decline, sparking fresh debate in dementia research
FDA releases 14 drug rejection letters after 3-month pause
The FDA has resumed the public release of drug rejection letters, issuing 14 new Complete Response Letters following a three-month operational pause.
Why your health plan doesn’t cover GLP-1s, according to a top insurance exec
Coverage explores shifting trends in health insurance coverage and alternative access models for GLP-1 weight-loss medications.